HPV vaccine effectiveness is demonstrated in new clinical and real-world data from Merck, showcasing the sustained protection of GARDASIL®9 (9-valent Human Papillomavirus [HPV] vaccine) and GARDASIL® (4-valent HPV vaccine) against HPV-related cancers and diseases. Key findings include vaccine eff...

The TAVI reimbursement expansion announced by Zorginstituut Nederland on March 10, 2026, includes transcatheter aortic valve implantation (TAVI) in...

The PRIME Scheme Evaluation of the European Medicines Agency’s (EMA) PRIority Medicines (PRIME), launched in 2016, confirms early and enhanced regulatory support accelerates medicines for unmet needs. A two-year pilot (April 2023–March 2025) tested three new features—regulatory roadmap and produc...

Imfinzi gastric cancer treatment has received European Commission approval for adults with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. AstraZeneca’s Imfinzi (durvalumab), a PD-L1 inhibitor, combined with FLOT chemotherapy...

Europe life sciences competitiveness is under pressure, as detailed in the EFPIA report "Asses...

This editorial by Petrou et al., published in the Journal of Medical Economics, critiques escalating pharmaceutical expenditures amid new therapies like glucagon-like peptide-1 (GLP-1) receptor agonists for ty...